Lite Strategy (LITS) Current Assets (2011 - 2026)
Lite Strategy (LITS) posted Current Assets of $11.0 million for Q1 2026, up 0.58% on a QoQ basis from $10.9 million in Q4 2025, and down 47.18% year-over-year from $20.8 million in Q1 2025.
Analysis
Lite Strategy (LITS) Current Assets (2011 - 2026) Analysis & Trends
Lite Strategy has reported Current Assets for 16 years, with the latest figure at $11.0 million in Q1 2026.
- On a quarterly basis, Current Assets fell 47.18% year-over-year to $11.0 million in Q1 2026; TTM through Mar 2026 was $11.0 million, a 47.18% decrease from a year earlier, with the FY2025 full-year figure at $18.3 million, down 55.15% from the prior year.
- Current Assets was $11.0 million for Q1 2026 at Lite Strategy, up from $10.9 million in the prior quarter.
- The five-year high for Current Assets was $183.5 million in Q1 2022, with the low at $10.9 million in Q4 2025.
- Average Current Assets over 5 years is $73.1 million, with a median of $59.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2024: Current Assets gained 3.91% in 2022, then plunged 68.62% in 2024.
- Over 5 years, Current Assets stood at $133.4 million in 2022, then plunged by 50.41% to $66.2 million in 2023, then plunged by 63.15% to $24.4 million in 2024, then sank by 55.25% to $10.9 million in 2025, then climbed by 0.58% to $11.0 million in 2026.
- The last three Current Assets figures came in at $11.0 million (Q1 2026), $10.9 million (Q4 2025), and $13.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 4.74 Bn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - | 10.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 10.98 Mn |
| Dec 31, 2025 | 10.91 Mn |
| Sep 30, 2025 | 13.24 Mn |
| Jun 30, 2025 | 18.29 Mn |
| Mar 31, 2025 | 20.78 Mn |
| Dec 31, 2024 | 24.39 Mn |
| Sep 30, 2024 | 27.75 Mn |
| Jun 30, 2024 | 40.77 Mn |
| Mar 31, 2024 | 59.37 Mn |
| Dec 31, 2023 | 66.17 Mn |
| Sep 30, 2023 | 88.42 Mn |
| Jun 30, 2023 | 107.53 Mn |
| Mar 31, 2023 | 120.48 Mn |
| Dec 31, 2022 | 133.45 Mn |
| Sep 30, 2022 | 148.91 Mn |
| Jun 30, 2022 | 167.13 Mn |
| Mar 31, 2022 | 183.47 Mn |
| Dec 31, 2021 | 200.73 Mn |
| Sep 30, 2021 | 167.36 Mn |
| Jun 30, 2021 | 164.82 Mn |